US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,423.58

+77.675.77%

Number of Gainers:9

Number of Losers:2

Number of Flat:- -

PE:- -

High:1,432.96

Open:1,345.95

Low:1,339.71

Close:1,345.91

Loading ...

Quest Diagnostics Launches Haystack MRD™: New ctDNA Blood Test for Early Cancer Recurrence Detection

Tonix Pharmaceuticals: Current Cash Sufficient to Fund Operations Into Q2 of 2026

THOMSON REUTERS

BRIEF-Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal For Contractors - SEC Filing

BRIEF-Viatris Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing

Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal for Contractors - SEC Filing

THOMSON REUTERS

Gilead Sciences Inc. Conducted Annual Stockholder Meeting

Tonix Pharmaceuticals Held Annual Shareholders Meeting

Viatris Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS

Emergent BioSolutions rises 29.3%

BUZZ-Viatris rises after quarterly results beat

Gilead put volume heavy and directionally bearish

Viatris Exec Says Continue to Explore Ways to Optimize Flexibility of Global Network, Including Potential to Increase Manufacturing Capacity in the US - Conf Call

THOMSON REUTERS

Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China

Viatris Q1 Adjusted EBITDA USD 923.5 Million

MORNING BID AMERICAS-UK eyes 'major trade deal'

Viatris Q1 Net Income USD -3,000 Million

THOMSON REUTERS

Viatris Inc: Non-Cash Goodwill Impairment Charge of $2.9 Bln in Current Quarter

THOMSON REUTERS

Viatris Q1 Adjusted EPS USD 0.5

THOMSON REUTERS

Viatris Q1 Gross Margin 35.7%

THOMSON REUTERS

BRIEF-Viatris Announces Positive Top-Line Results From Two Pivotal Phase 3 Studies Of Novel Fast-Acting Meloxicam (Mr-107A-02) For The Treatment Of Moderate-To-Severe Acute Pain

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1423.5786,"timestamp":1747079999999,"preClose":1345.9122,"halted":0,"volume":30808658,"delay":0,"changeRate":0.057705,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":77.666382,"latestTime":"05-12 16:00:00 EDT","open":1345.9465,"high":1432.9608,"low":1339.7142,"amount":1688764996.986356,"amplitude":0.069281,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747143000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.544967,"peRate":56.071544,"turnoverRate":0.011447,"increases":9,"decrements":2,"flats":0,"marketCap":160284529166.5,"floatMarketCap":159626471081},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1432.9608,"amplitude":0.069281,"preClose":1345.9122,"low":1339.7142,"pbRate":"3.544967","latestPrice":1423.5786,"volume":30808658,"delay":0,"open":1345.9465,"prevYearClose":1284.7982,"prevWeekClose":1345.9122,"prevMonthClose":1449.9094,"prevQuarterClose":1502.9401,"fiveDayClose":1409.4836,"twentyDayClose":1393.7178,"sixtyDayClose":1457.112,"secType":"PLATE","market":"US","turnoverRate":0.011447,"peRate":56.071544,"marketCap":160284529166.5,"floatMarketCap":159626471081,"timestamp":1747079999999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":9,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535749208","title":"Quest Diagnostics Launches Haystack MRD™: New ctDNA Blood Test for Early Cancer Recurrence Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2535749208","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535749208?lang=en_us&edition=fundamental","pubTime":"2025-05-13 18:03","pubTimestamp":1747130601,"startTime":"0","endTime":"0","summary":"Quest Diagnostics Incorporated has announced the launch of its first ctDNA minimal residual disease  test, Haystack MRD, aimed at improving cancer monitoring for patients treated for solid tumors. The launch comes as part of a response to the increasing prevalence of advanced-stage cancers and the associated challenges in early detection of cancer recurrence. A recent survey conducted by The Harris Poll on behalf of Quest Diagnostics highlights that 76% of oncologists are observing more advanced cancers, with 94% believing that ctDNA MRD testing could significantly reduce delays in diagnosing cancer recurrence. Despite the promise of these new tests, oncologists acknowledge hurdles to their wide adoption. The Haystack MRD test is part of Quest Diagnostics' efforts to provide innovative solutions amid growing concerns of cancer recurrence among survivors, expected to reach 26 million by 2040.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL9n0bwf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4583","LU1854104046.USD","BK4588","BK4196","DGX","BK4567","LU1854103824.USD"],"gpt_icon":0},{"id":"2535784689","title":"Tonix Pharmaceuticals: Current Cash Sufficient to Fund Operations Into Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2535784689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535784689?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:30","pubTimestamp":1747081801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nPLXBA6AAB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNXP","BK4139","BK4583"],"gpt_icon":0},{"id":"2534934711","title":"BRIEF-Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal For Contractors - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534934711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534934711?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:25","pubTimestamp":1746743103,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal For Contractors - SEC FilingGilead Sciences Inc GILD.O:GILEAD SCIENCES INC - STOCKHOLDERS REJECT DEI PRACTICES RISK REPORT PROPOSAL FOR CONTRACTORS - SEC FILINGGILEAD SCIENCES INC - STOCKHOLDERS REJECT INDEPENDENT BOARD CHAIR POLICY PROPOSAL - SEC FILINGSource text: [ID:n0000882095-25-000015]Further company coverage: GILD.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1066053197.SGD","LU1066051498.USD","BK4568","BK4532","LU2087621335.USD","BK4566","LU1430594728.SGD","LU1674673691.USD","IE0002270589.USD","LU2468319806.SGD","LU1585245621.USD","GILD","IE00BZ1G4Q59.USD","BK4578","LU0320765992.SGD","IE00B3T34201.USD","BK4139","BK4585","BK4583","BK4550","LU1674673428.USD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0058720904.USD","LU2089984988.USD","LU0889565916.HKD","IE00BSNM7G36.USD","LU1839511570.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","LU1778281490.HKD","LU0109394709.USD","LU1571399168.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2534193137","title":"BRIEF-Viatris Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534193137","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534193137?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:20","pubTimestamp":1746742819,"startTime":"0","endTime":"0","summary":"BRIEF-Viatris Inc Files For Mixed Shelf Size Not Disclosed - SEC FilingViatris Inc VTRS.O:VIATRIS INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILINGSource text: [ID:n0001140361-25-017967]Further company coverage: VTRS.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2087621335.USD","BK4583","BK4585","BK4588","LU1839511570.USD","VTRS"],"gpt_icon":0},{"id":"2534719332","title":"Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal for Contractors - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534719332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534719332?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:13","pubTimestamp":1746742433,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1674673691.USD","LU2087621335.USD","IE00B7SZLL34.SGD","LU0058720904.USD","LU2089984988.USD","BK4139","IE00B19Z3B42.SGD","BK4550","BK4588","IE00BZ1G4Q59.USD","BK4578","GILD","LU0320765992.SGD","LU1585245621.USD","BK4585","BK4568","BK4583","LU0234570918.USD","LU1066053197.SGD","LU1430594728.SGD","LU1674673428.USD","LU1066051498.USD","IE00BKVL7J92.USD","LU0109394709.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1839511570.USD","BK4532","BK4566","LU1778281490.HKD","LU0289739699.SGD","LU1571399168.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0889565916.HKD","IE0002270589.USD"],"gpt_icon":0},{"id":"2534953411","title":"Gilead Sciences Inc. Conducted Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2534953411","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534953411?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:06","pubTimestamp":1746741995,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc. held its annual meeting of stockholders on May 7, 2025. Stockholders elected nine directors. A proposal for an independent Board Chair policy was not approved. A proposal requesting a comprehensive human rights policy and due diligence process was not approved. A proposal requesting a report on the risks of DEI practices for contractors was not approved. A proposal requesting the CEO pay ratio factor be included in executive compensation programs was not approved. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL6fk5vT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU2089984988.USD","LU1585245621.USD","BK4578","LU1066051498.USD","IE00B3T34201.USD","BK4139","BK4588","LU0320765992.SGD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU1839511570.USD","IE0002270589.USD","LU2087621335.USD","LU1430594728.SGD","LU1778281490.HKD","BK4568","IE00B19Z3B42.SGD","LU0234570918.USD","GILD","LU2468319806.SGD","IE00B19Z3581.USD","BK4585","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BK4550","LU0109394709.USD","LU1674673691.USD","IE00BKVL7J92.USD","BK4532","LU1571399168.USD","LU0889565916.HKD","BK4566","BK4583","LU0289739699.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2534195319","title":"Tonix Pharmaceuticals Held Annual Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2534195319","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534195319?lang=en_us&edition=fundamental","pubTime":"2025-05-09 05:53","pubTimestamp":1746741228,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp. conducted its annual meeting of shareholders on May 8, 2025. Shareholders approved several proposals during the meeting. Eight individuals were elected to the Board of Directors. The amendment to the Company's Amended and Restated Stock 2020 Stock Incentive Plan, increasing the number of shares available for awards, was approved. The 2025 Employee Stock Purchase Plan received approval. The authorization for the Board of Directors to effect one or more reverse stock splits within a specified range was also approved. Additionally, the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL1DmJ9S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4139","BK4583"],"gpt_icon":0},{"id":"2534164889","title":"Viatris Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534164889","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534164889?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:32","pubTimestamp":1746736332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU1839511570.USD","BK4588","BK4583","LU2087621335.USD","BK4007","VTRS"],"gpt_icon":0},{"id":"2534567811","title":"Emergent BioSolutions rises 29.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534567811","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534567811?lang=en_us&edition=fundamental","pubTime":"2025-05-09 00:06","pubTimestamp":1746720363,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions (EBS) is up 29.3%, or $1.39 to $6.13. Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emergent-biosolutions-rises-29-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emergent-biosolutions-rises-29-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2533153650","title":"BUZZ-Viatris rises after quarterly results beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2533153650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533153650?lang=en_us&edition=fundamental","pubTime":"2025-05-08 23:45","pubTimestamp":1746719103,"startTime":"0","endTime":"0","summary":"BUZZ-Viatris rises after quarterly results beatUpdates** Shares of generic drugmaker Viatris VTRS.O rise as much as 10.1% to a near two-month high of $9.47** VTRS posts Q1 adj. profit of 50 cents per share, compared with analysts' estimate of 49 cents per share, according to data compiled by LSEG ** Co reports Q1 revenue of $3.25 billion vs estimates of $3.23 billion ** VTRS expects 2025 adj. profit between $2.12 and $2.26 per share, compared with estimate of $2.59 per share ** Co says \"it continues to explore ways to optimize the flexibility of our global network, including the potential to increase our manufacturing capacity in the U.S.\" as a way to mitigate potential tariffs** Separately, VTRS also says its fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies, and a lower dose version of its birth control patch, called Xulane, also met all the main goals of a late-stage study** Including session's move, stock down 25.3%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL4N3RG28G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS","BK4583","LU2087621335.USD","BK4007","LU1839511570.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2533132699","title":"Gilead put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2533132699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533132699?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:40","pubTimestamp":1746715228,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Gilead (GILD) with 3,289 puts trading, or 2x expected. Most active are Jan-26 90 puts and Jun-25 90 puts, with total volume i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-6?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-6?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2087621335.USD","BK4566","LU2089984988.USD","LU1839511570.USD","LU0320765992.SGD","BK4583","BK4532","BK4550","IE00B7SZLL34.SGD","LU1674673428.USD","LU0109394709.USD","LU1778281490.HKD","IE00B3T34201.USD","BK4568","LU1585245621.USD","LU1571399168.USD","BK4585","LU1066051498.USD","BK4588","LU2468319806.SGD","IE00B19Z3B42.SGD","BK4578","GILD","LU1430594728.SGD","LU0889565916.HKD","LU1674673691.USD","BK4139","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU0234570918.USD","IE0002270589.USD","LU0289739699.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2533187647","title":"Viatris Exec Says Continue to Explore Ways to Optimize Flexibility of Global Network, Including Potential to Increase Manufacturing Capacity in the US - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2533187647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533187647?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:40","pubTimestamp":1746708039,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG374:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","LU1839511570.USD","LU2087621335.USD","VTRS","BK4583","BK4007"],"gpt_icon":0},{"id":"2533706184","title":"Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2533706184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533706184?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:17","pubTimestamp":1746706639,"startTime":"0","endTime":"0","summary":"Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China May 8 (Reuters) - Drugmaker Viatris VTRS.O beat Wall Street estimates for first-quarter profit and revenue on Thursd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL4N3RG1H0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","BK4583","LU0058720904.USD","LU0289739699.SGD","SG9999001176.USD","LU0225284248.USD","LU1883839398.USD","IE0002270589.USD","LU1023059063.AUD","VTRS","BK4599","SG9999002224.SGD","LU0234572021.USD","IE000M9KFDE8.USD","LU0306806265.USD","BK4588","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4533","LU0170899867.USD","BK4550","SG9999003800.SGD","LU0122379950.USD","SG9999011175.SGD","LU2087621335.USD","BK4585","LU0321505868.SGD","LU0985481810.HKD","IE00BLSP4452.SGD","BK4568","IE00BBT3K403.USD","BK4592","LU0456855351.SGD","LU1066051498.USD","LU0225771236.USD","LU1057294990.SGD","LU1839511570.USD","LU1894683348.USD","SG9999013999.USD","BK4007","IE00BLSP4239.USD","BK4581","LU1066053197.SGD","SG9999001176.SGD","SGXZ57979304.SGD","LU0306807586.USD","LU0321505439.SGD","BK4534","SG9999002232.USD"],"gpt_icon":1},{"id":"2533183134","title":"Viatris Q1 Adjusted EBITDA USD 923.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183134?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:10","pubTimestamp":1746702636,"startTime":"0","endTime":"0","summary":"May 08 (Reuters) - Viatris Q1 revenue USD 3,254.3 million vs. IBES estimate USD 3,235 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 08-MAY-202510:59:53.713 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nRSD7rZ9cC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","LU2087621335.USD","BK4583","BK4585","LU1839511570.USD","VTRS"],"gpt_icon":0},{"id":"2533839821","title":"MORNING BID AMERICAS-UK eyes 'major trade deal'","url":"https://stock-news.laohu8.com/highlight/detail?id=2533839821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533839821?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:07","pubTimestamp":1746702444,"startTime":"0","endTime":"0","summary":"LONDON, May 8  - What matters in U.S. and global markets todayBy Mike Dolan, Editor-At-Large, Financial Industry and Financial MarketsThe spotlight hit Britain on Thursday as U.S. President Donald Trump's 'major trade deal' announcement looks set to provide a major relief for UK exporters, just as the Bank of England is set to cut interest rates.I'll get into all the market news below, and, for today's deep dive, I'll explain why Europe may be better prepared to absorb a deluge of global investment flows than many assume.Reuters' columnist Ron Bousso explores this discrepancy.* Concern is mounting over just how big a hit the Chinese economy is going to take from the trade war with the United States, but so far the commodity most at risk - iron ore - is seemingly unaffected. Reuters' columnist Clyde Russell explains why in his latest piece.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"aecd65ff4b420192909af2a6c862df92","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL4N3RG15R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4570","BK4583","LNT","LU0630314457.HKD","LU1064131342.USD","KVUE","COP","LU2286300806.USD","NWSA","WBD","TAP","LU0708994859.HKD","LU0251142724.SGD","LU1934455277.USD","LU2125910500.SGD","LU2357305700.SGD","LU1074936037.SGD","AKAM","PARA","BK4175","LU0047713382.USD","LU1057294990.SGD","PODD","EXPE","LU0345780950.USD","LU0456854461.SGD","LU2362540622.SGD","MCHP","MCK","SRE","LU2362541513.USD","EPAM","BK4585","LU2112291526.USD","LU1621768115.EUR","LU1061106388.HKD","LU0942090050.USD","LU0130102774.USD","LU2346227817.USD","IE00B0169N27.USD","IE00BFXG1179.USD","LU0306806265.USD","BK4529","BK4183","LU1934455863.HKD","VTRS","LU0122379950.USD","LU0965509010.AUD","LU1037948897.HKD","LU2089984988.USD"],"gpt_icon":0},{"id":"2533900713","title":"Viatris Q1 Net Income USD -3,000 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533900713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533900713?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:59","pubTimestamp":1746701948,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX59458B:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU1839511570.USD","VTRS","BK4585","LU2087621335.USD","BK4583","BK4588"],"gpt_icon":0},{"id":"2533882051","title":"Viatris Inc: Non-Cash Goodwill Impairment Charge of $2.9 Bln in Current Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2533882051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533882051?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:59","pubTimestamp":1746701948,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX59458B:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1839511570.USD","BK4585","LU2087621335.USD","BK4588","BK4583","BK4007","VTRS"],"gpt_icon":0},{"id":"2533007929","title":"Viatris Q1 Adjusted EPS USD 0.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2533007929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533007929?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:59","pubTimestamp":1746701948,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX59458B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","VTRS","BK4007","BK4583","LU2087621335.USD","LU1839511570.USD","BK4588"],"gpt_icon":0},{"id":"2533007769","title":"Viatris Q1 Gross Margin 35.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533007769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533007769?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:59","pubTimestamp":1746701948,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX59458B:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU1839511570.USD","VTRS","BK4585","LU2087621335.USD","BK4583","BK4588"],"gpt_icon":0},{"id":"2533900220","title":"BRIEF-Viatris Announces Positive Top-Line Results From Two Pivotal Phase 3 Studies Of Novel Fast-Acting Meloxicam (Mr-107A-02) For The Treatment Of Moderate-To-Severe Acute Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2533900220","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533900220?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:56","pubTimestamp":1746701817,"startTime":"0","endTime":"0","summary":"BRIEF-Viatris Announces Positive Top-Line Results From Two Pivotal Phase 3 Studies Of Novel Fast-Acting Meloxicam (Mr-107A-02) For The Treatment Of Moderate-To-Severe Acute PainMay 8 (Reuters) - Viatr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VTRS","BK4007","BK4583","LU1839511570.USD","LU2087621335.USD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}]}}